$PLXP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PLx Pharma Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PLx Pharma Inc.. Get notifications about new insider transactions in PLx Pharma Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 09 2021 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Buy | P | 8.00 | 25,000 | 200,000 | 486,690 | 461.7 K to 486.7 K (+5.41 %) |
| Dec 15 2020 | PLXP | PLx Pharma Inc. | HADDEN JOHN | Director | Buy | P | 5.49 | 400 | 2,196 | 3,690 | 3.3 K to 3.7 K (+12.16 %) |
| Dec 15 2020 | PLXP | PLx Pharma Inc. | HADDEN JOHN | Director | Buy | P | 5.42 | 600 | 3,252 | 3,290 | 2.7 K to 3.3 K (+22.30 %) |
| Nov 25 2020 | PLXP | PLx Pharma Inc. | HADDEN JOHN | Director | Buy | P | 5.48 | 500 | 2,738 | 2,690 | 2.2 K to 2.7 K (+22.83 %) |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | P | 4.31 | 291,390 | 1,255,891 | 291,390 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | A | 5.15 | 160,000 | 824,000 | 160,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Buy | P | 3.79 | 264,900 | 1,003,176 | 461,690 | 196.8 K to 461.7 K (+134.61 %) |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | P | 4.31 | 291,390 | 1,255,891 | 291,390 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | A | 5.15 | 160,000 | 824,000 | 160,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Buy | P | 3.79 | 264,900 | 1,003,176 | 461,690 | 196.8 K to 461.7 K (+134.61 %) |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Option Exercise | A | 5.15 | 174,000 | 896,100 | 174,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | HADDEN JOHN | Director | Option Exercise | A | 5.15 | 40,000 | 206,000 | 40,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Giordano Natasha | Chief Executive Off ... | Option Exercise | A | 5.15 | 350,000 | 1,802,500 | 350,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Casale Robert | Director | Option Exercise | A | 5.15 | 40,000 | 206,000 | 40,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | CALHOUN KIRK K | Director | Option Exercise | A | 5.15 | 40,000 | 206,000 | 40,000 | |
| Nov 20 2020 | PLXP | PLx Pharma Inc. | Balkema Gary S. | Director | Option Exercise | A | 5.15 | 40,000 | 206,000 | 40,000 | |
| Sep 03 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Buy | P | 3.83 | 2,120 | 8,127 | 12,970 | 10.9 K to 13 K (+19.54 %) |
| Sep 03 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Buy | P | 3.74 | 4,500 | 16,837 | 10,850 | 6.4 K to 10.9 K (+70.87 %) |
| Sep 03 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Buy | P | 3.83 | 2,120 | 8,127 | 12,970 | 10.9 K to 13 K (+19.54 %) |
| Sep 03 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Buy | P | 3.74 | 4,500 | 16,837 | 10,850 | 6.4 K to 10.9 K (+70.87 %) |
| Aug 24 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Buy | P | 3.97 | 4,050 | 16,091 | 6,350 | 2.3 K to 6.4 K (+176.09 %) |
| Aug 24 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Buy | P | 3.77 | 2,300 | 8,666 | 2,300 | 0 to 2.3 K |
| May 19 2020 | PLXP | PLx Pharma Inc. | Park West Asset Management LLC | 10% Owner | Option Exercise | P | 3.10 | 6,000 | 18,600 | 6,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | A | 2.16 | 80,000 | 172,800 | 80,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Option Exercise | A | 2.16 | 87,000 | 187,920 | 87,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | HADDEN JOHN | Director | Option Exercise | A | 2.16 | 20,000 | 43,200 | 20,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | Giordano Natasha | Chief Executive Off ... | Option Exercise | A | 2.16 | 175,000 | 378,000 | 175,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | Deliargyris Efthymios | Chief Medical Offic ... | Option Exercise | A | 2.16 | 60,000 | 129,600 | 60,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | Casale Robert | Director | Option Exercise | A | 2.16 | 20,000 | 43,200 | 20,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | CALHOUN KIRK K | Director | Option Exercise | A | 2.16 | 20,000 | 43,200 | 20,000 | |
| Mar 24 2020 | PLXP | PLx Pharma Inc. | Balkema Gary S. | Director | Option Exercise | A | 2.16 | 20,000 | 43,200 | 20,000 | |
| May 21 2019 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Buy | P | 5.60 | 44,404 | 248,662 | 196,790 | 152.4 K to 196.8 K (+29.14 %) |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | CALHOUN KIRK K | Director | Option Exercise | A | 5.79 | 20,000 | 115,800 | 20,000 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | Balkema Gary S. | Director | Option Exercise | A | 5.79 | 20,000 | 115,800 | 20,000 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | A | 5.79 | 80,000 | 463,200 | 80,000 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | O'Connor Rita M | Chief Financial Off ... | Option Exercise | A | 5.79 | 123,675 | 716,078 | 123,675 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | HADDEN JOHN | Director | Option Exercise | A | 5.79 | 20,000 | 115,800 | 20,000 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | Giordano Natasha | Chief Executive Off ... | Option Exercise | A | 5.79 | 211,675 | 1,225,598 | 211,675 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | Deliargyris Efthymios | Chief Medical Offic ... | Option Exercise | A | 5.79 | 60,000 | 347,400 | 60,000 | |
| Mar 18 2019 | PLXP | PLx Pharma Inc. | Casale Robert | Director | Option Exercise | A | 5.79 | 20,000 | 115,800 | 20,000 | |
| Feb 22 2019 | PLXP | PLx Pharma Inc. | Park West Asset Management LLC | 10% Owner | Option Exercise | P | 2.60 | 15,000 | 39,000 | 15,000 | |
| Dec 31 2018 | PLXP | PLx Pharma Inc. | Park West Asset Management LLC | 10% Owner | Option Exercise | P | 3.50 | 500,000 | 1,750,000 | 500,000 | |
| Dec 31 2018 | PLXP | PLx Pharma Inc. | Park West Asset Management LLC | 10% Owner | Buy | P | 1.00 | 397,495 | 397,495 | 1,473,218 | 1.1 M to 1.5 M (+36.95 %) |
| Aug 31 2018 | PLXP | PLx Pharma Inc. | Deliargyris Efthymios | Chief Medical Offic ... | Option Exercise | A | 3.18 | 70,000 | 222,600 | 70,000 | |
| Aug 14 2017 | DPRX | PLx Pharma Inc. | Giordano Natasha | CEO | Option Exercise | A | 6.72 | 86,872 | 583,780 | 86,872 | |
| Aug 14 2017 | DPRX | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Grant | A | 0.00 | 30,000 | 0 | 152,386 | 122.4 K to 152.4 K (+24.51 %) |
| Jun 16 2017 | DPRX | PLx Pharma Inc. | JORDEN DAVID EMERSON | Acting Chief Financ ... | Option Exercise | P | 7.50 | 32,727 | 245,453 | 32,727 | |
| Jun 16 2017 | DPRX | PLx Pharma Inc. | JORDEN DAVID EMERSON | Acting Chief Financ ... | Buy | P | 6.88 | 32,727 | 224,998 | 151,913 | 119.2 K to 151.9 K (+27.46 %) |
| Jun 16 2017 | DPRX | PLx Pharma Inc. | MOSSMAN GARY L | Chief Operating Off ... | Option Exercise | P | 7.50 | 7,273 | 54,548 | 7,273 | |
| Jun 16 2017 | DPRX | PLx Pharma Inc. | MOSSMAN GARY L | Chief Operating Off ... | Buy | P | 6.88 | 7,273 | 50,002 | 78,255 | 71 K to 78.3 K (+10.25 %) |
| Jun 16 2017 | DPRX | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | P | 7.50 | 29,091 | 218,183 | 29,091 | |
| Jun 16 2017 | DPRX | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Buy | P | 6.88 | 29,091 | 200,001 | 122,386 | 93.3 K to 122.4 K (+31.18 %) |
| Apr 21 2017 | DPRX | PLx Pharma Inc. | LUCI DAVID P | Director | Option Exercise | D | 13.93 | 298,826 | 4,162,646 | 0 | |
| Apr 21 2017 | DPRX | PLx Pharma Inc. | LUCI DAVID P | Director | Option Exercise | A | 1.80 | 275,000 | 495,000 | 275,000 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Option Exercise | A | 12.44 | 112,509 | 1,399,612 | 112,509 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Valentino Michael J | Executive Chairman | Grant | A | 0.00 | 93,295 | 0 | 93,295 | 0 to 93.3 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | MOSSMAN GARY L | Chief Operating Off ... | Option Exercise | A | 12.44 | 69,755 | 867,752 | 69,755 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | MOSSMAN GARY L | Chief Operating Off ... | Grant | A | 0.00 | 2,009 | 0 | 2,009 | 0 to 2 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | MOSSMAN GARY L | Chief Operating Off ... | Grant | A | 0.00 | 14,955 | 0 | 14,955 | 0 to 15 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | MOSSMAN GARY L | Chief Operating Off ... | Grant | A | 0.00 | 70,982 | 0 | 70,982 | 0 to 71 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | JORDEN DAVID EMERSON | Acting Chief Financ ... | Option Exercise | A | 12.44 | 33,753 | 419,887 | 33,753 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | JORDEN DAVID EMERSON | Acting Chief Financ ... | Grant | A | 0.00 | 119,186 | 0 | 119,186 | 0 to 119.2 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | HADDEN JOHN | Director | Option Exercise | A | 12.44 | 9,002 | 111,985 | 9,002 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | HADDEN JOHN | Director | Grant | A | 0.00 | 2,190 | 0 | 2,190 | 0 to 2.2 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Giordano Natasha | President and CEO | Option Exercise | A | 12.44 | 216,580 | 2,694,255 | 216,580 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Giordano Natasha | President and CEO | Grant | A | 0.00 | 1,086 | 0 | 1,086 | 0 to 1.1 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Casale Robert | Director | Option Exercise | A | 12.44 | 9,002 | 111,985 | 9,002 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Casale Robert | Director | Grant | A | 0.00 | 2,710 | 0 | 2,710 | 0 to 2.7 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | CALHOUN KIRK K | Director | Option Exercise | A | 12.44 | 9,002 | 111,985 | 9,002 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | CALHOUN KIRK K | Director | Grant | A | 0.00 | 1,675 | 0 | 1,675 | 0 to 1.7 K |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Balkema Gary S. | Director | Option Exercise | A | 12.44 | 9,002 | 111,985 | 9,002 | |
| Apr 20 2017 | DPRX | PLx Pharma Inc. | Balkema Gary S. | Director | Grant | A | 0.00 | 5,445 | 0 | 5,445 | 0 to 5.4 K |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | Shawah Robert G. | Chief Accounting Of ... | Option Exercise | A | 1.80 | 130,000 | 234,000 | 130,000 | |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | McSherry, Jr. William J. | Director | Option Exercise | A | 1.80 | 20,000 | 36,000 | 20,000 | |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | Kagan Barry | Director | Option Exercise | A | 1.80 | 20,000 | 36,000 | 20,000 | |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | HARRISON THOMAS L | Director | Option Exercise | A | 1.80 | 20,000 | 36,000 | 20,000 | |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | DEAN JACK H | Director | Option Exercise | A | 1.80 | 20,000 | 36,000 | 20,000 | |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | Duffy Michael E. | Director | Option Exercise | A | 1.80 | 20,000 | 36,000 | 20,000 | |
| Apr 20 2017 | DPRX | Dipexium Pharmaceu ... | DELUCCIA ROBERT J | Executive Chairman | Option Exercise | A | 1.80 | 183,332 | 329,998 | 183,332 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | McSherry, Jr. William J. | Director | Option Exercise | A | 10.16 | 18,000 | 182,880 | 18,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | Garrett David | VP Finance & Corp. ... | Option Exercise | A | 10.16 | 35,000 | 355,600 | 35,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | LUCI DAVID P | President, CEO, Sec ... | Option Exercise | A | 10.16 | 35,000 | 355,600 | 35,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | DELUCCIA ROBERT J | Executive Chairman | Option Exercise | A | 10.16 | 35,000 | 355,600 | 35,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | Kagan Barry | Director | Option Exercise | A | 10.16 | 18,000 | 182,880 | 18,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | DEAN JACK H | Director | Option Exercise | A | 10.16 | 18,000 | 182,880 | 18,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | Duffy Michael E. | Director | Option Exercise | A | 10.16 | 18,000 | 182,880 | 18,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | Shawah Robert G. | Chief Accounting Of ... | Option Exercise | A | 10.16 | 65,000 | 660,400 | 65,000 | |
| Jan 21 2016 | DPRX | Dipexium Pharmaceu ... | HARRISON THOMAS L | Director | Option Exercise | A | 10.16 | 18,000 | 182,880 | 18,000 | |
| Feb 18 2015 | DPRX | Dipexium Pharmaceu ... | McSherry, Jr. William J. | Director | Option Exercise | A | 11.35 | 15,000 | 170,250 | 15,000 | |
| Feb 02 2015 | DPRX | Dipexium Pharmaceu ... | DEAN JACK H | Director | Option Exercise | A | 11.35 | 15,000 | 170,250 | 15,000 | |
| Jan 29 2015 | DPRX | Dipexium Pharmaceu ... | Garrett David | VP, Finance & Corp. ... | Option Exercise | A | 11.35 | 35,000 | 397,250 | 205,756 | |
| Jan 29 2015 | DPRX | Dipexium Pharmaceu ... | LUCI DAVID P | President, CEO, Sec ... | Option Exercise | A | 11.35 | 35,000 | 397,250 | 333,826 | |
| Jan 29 2015 | DPRX | Dipexium Pharmaceu ... | Shawah Robert G. | Chief Accounting Of ... | Option Exercise | A | 11.35 | 35,000 | 397,250 | 120 | |
| Jan 29 2015 | DPRX | Dipexium Pharmaceu ... | HARRISON THOMAS L | Director | Option Exercise | A | 11.35 | 15,000 | 170,250 | 15,000 | |
| Jan 29 2015 | DPRX | Dipexium Pharmaceu ... | Duffy Michael E. | Director | Option Exercise | A | 11.35 | 15,000 | 170,250 | 15,000 | |
| Jan 29 2015 | DPRX | Dipexium Pharmaceu ... | DELUCCIA ROBERT J | Executive Chairman | Option Exercise | A | 11.35 | 35,000 | 397,250 | 333,826 | |
| May 22 2014 | DPRX | Dipexium Pharmaceu ... | DEAN JACK H | Director | Buy | P | 9.00 | 3,000 | 27,000 | 48,917 | 45.9 K to 48.9 K (+6.53 %) |
| Mar 20 2014 | DPRX | Dipexium Pharmaceu ... | COUGHLIN CHRISTOPHER J | Director | Buy | P | 12.00 | 2,083 | 24,996 | 109,309 | 107.2 K to 109.3 K (+1.94 %) |
| Mar 20 2014 | DPRX | Dipexium Pharmaceu ... | DEAN JACK H | Director | Buy | P | 12.00 | 2,083 | 24,996 | 45,917 | 43.8 K to 45.9 K (+4.75 %) |
| Mar 20 2014 | DPRX | Dipexium Pharmaceu ... | HARRISON THOMAS L | Director | Buy | P | 12.00 | 2,000 | 24,000 | 148,832 | 146.8 K to 148.8 K (+1.36 %) |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | Shawah Robert G. | Chief Accounting Of ... | Option Exercise | A | 13.93 | 85,379 | 1,189,329 | 85,379 | |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | Shawah Robert G. | Chief Accounting Of ... | Buy | P | 12.00 | 500 | 6,000 | 500 | 0 to 500 |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | LUCI DAVID P | President, CEO, Sec ... | Option Exercise | A | 13.93 | 298,826 | 4,162,646 | 298,826 | |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | LUCI DAVID P | President, CEO, Sec ... | Buy | P | 12.00 | 2,083 | 24,996 | 1,829,447 | 1.8 M to 1.8 M (+0.11 %) |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | Garrett David | VP, Finance & Corp. ... | Option Exercise | A | 13.93 | 170,756 | 2,378,631 | 170,756 | |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | Garrett David | VP, Finance & Corp. ... | Buy | P | 12.00 | 2,083 | 24,996 | 10,007 | 7.9 K to 10 K (+26.29 %) |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | DELUCCIA ROBERT J | Executive Chairman | Option Exercise | A | 13.93 | 298,826 | 4,162,646 | 298,826 | |
| Mar 19 2014 | DPRX | Dipexium Pharmaceu ... | DELUCCIA ROBERT J | Executive Chairman | Buy | P | 12.00 | 2,083 | 24,996 | 1,813,669 | 1.8 M to 1.8 M (+0.11 %) |
Page: 1